| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T549 |
0-138 |
Sentence |
denotes |
Antibody-based therapy is being considered as a potential intervention for COVID-19, owing to the successful preliminary results with CPT. |
| T550 |
139-317 |
Sentence |
denotes |
However, this treatment approach may be associated with the risk of exacerbating COVID-19 severity, based on the experience from previous viral infections (Salazar et al., 2017). |
| T551 |
318-536 |
Sentence |
denotes |
Further, like previous SARS-CoV infections, antibody response may not always favor viral clearance, instead of contributing to the underlying immunopathology in some instances (Zhang et al., 2006; Newton et al., 2016). |
| T552 |
537-766 |
Sentence |
denotes |
This immunopathological state may thus attribute to factors such as robust and unregulated activation of B cells, ADE, presence of cross-reactive but non-neutralizing antibodies, and failure to mount a controlled B cell response. |
| T553 |
767-963 |
Sentence |
denotes |
Across studies, higher antibody titers detected in patients with severe and critical condition in comparison to non-severe cases (Long et al., 2020a; Gudbjartsson et al., 2020; Zhao et al., 2020). |
| T554 |
964-1229 |
Sentence |
denotes |
One can argue that higher antibody titer should be beneficial to provide an adequate antiviral response but can be countered by the finding that higher antibody titers found in a large number of severe cases and patients requiring ventilation (Kaneko et al., 2020). |
| T555 |
1230-1393 |
Sentence |
denotes |
This contradiction is yet to resolve, and the emerging data suggest that higher antibody response may reflect the over-activation and uncontrolled B cell response. |
| T556 |
1394-1518 |
Sentence |
denotes |
Zheng M. et al. (2020) showed the presence of RBD-specific IgG and IgA antibodies in patients with severe disease condition. |
| T557 |
1519-1594 |
Sentence |
denotes |
The study included 13 severe and 41 non-severe cases of various age groups. |
